Laboratory Products
COVID-19 Diagnostic Tests Detect all Published Virus Strains
Jan 14 2021
Novacyt announces that following the detection of a new variant of COVID-19 by the UK’s COVID-19 Genomics UK consortium, known as VUI-202012/01, the company has carried out a detailed analysis of the mutations in this new variant and in all published COVID-19 strains to fully assess the reliability of its existing diagnostic tests.
The results of the in silico (computer simulation) analysis of the sequenced mutations show that the company’s polymerase chain reaction product portfolio, based around a single and a two gene target for COVID-19, remain able to detect all published COVID-19 strains with the same high level of accuracy, including VUI-202012/01.
The company notes this new strain of the virus has also been identified in other countries, including the Netherlands, Denmark and Australia.
Graham Mullis, Chief Executive Officer of Novacyt, commented: “These data support the continued use of our tests, which remain accurate in detecting all published strains of COVID-19, including the latest variant. As part of our surveillance programme, we are committed to analysing our selected gene targets for COVID-19 against new published viral sequences to demonstrate ongoing accuracy and performance. We also remain in close contact with the Department of Health and Social Care and the NHS as we continue to focus our efforts on deploying our tests to hospitals and laboratories across the UK, as well as to our customers around the world.”
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 07 2024 Dublin, Ireland
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia